Biolegend, 339807, APC anti-BrdU Antibody, 25tests

BrdU is a uridine derivative and a structural analog of thymidine that can be incorporated into DNA during the S-phase of the cell cycle as a substitute for thymidine. Cells can be pulse-labeled with BrdU and analyzed with antibodies against BrdU to determine the proportion of cells in the S-phase of the cell cycle during a given interval.
25tests
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: ICFC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent intracellular staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Red Laser (633 nm)
Application Notes: Additional reported applications include: immunohistochemical staining of formalin fixed paraffin embedded tissue sections.
Application References(PubMed link indicates BioLegend citation): Magaud J-P, et al. 1989. J. Histochem. Cytochem. 37:1517. Ejassi-Lassallette A, et al. 2011. 22:245. PubMed Ma L, et al. 2012 PNAS. 109:2090. PubMed.
Product Citations: Vick SC, et al. 2021. J Immunol. 207:2598. PubMed Hu Q, et al. 2022. Cell Rep. 40:111035. PubMed Morrison K, et al. 2019. Cell Rep. 29:2961. PubMed Ancey PB, et al. 2021. Cancer Res. 81:2345. PubMed Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed Kamei A, et al. 2016. Proc Natl Acad Sci U S A. 113: E6153 - E6161. PubMed Sundaravinayagam D et al. 2019. Cell Rep. 28(6):1389-1399 . PubMed Ferrandino F, et al. 2018. Oncogene. 37:6285. PubMed Paschalis EI, et al. 2018. Proc Natl Acad Sci U S A. 115:E11359. PubMed Jimenez RV, et al. 2019. Front Immunol. 1.932638889. PubMed Tan Y, et al. 2014. PLoS One. 9:111777. PubMed Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed Branigan TB, et al. 2021. Cell Reports. 34(9):108808. PubMed Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed Xing M, et al. 2020. Molecular Cell. 78(4):714-724. PubMed Rochford I, et al. 2021. Am J Physiol Lung Cell Mol Physiol. 321:L686. PubMed Joshi JC, et al. 2020. Cell Rep. 30:4096. PubMed Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
RRID: AB_10900446 (BioLegend Cat. No. 339807) AB_10895898 (BioLegend Cat. No. 339808)
Structure: Uridine derivative that can be incorporated into DNA and substitute for thymidine residues.
Distribution: Cells can be pulsed labeled with BrdU which will be incorporated into DNA during the synthesis phase of the cell cycle.
Function: Antibody against BrdU can be used to identify cells undergoing DNA replication during the period of BrdU incorporation.
Biology Area: Cell Biology, Cell Cycle/DNA Replication, Immunology
Molecular Family: Nuclear Markers
Antigen References: 1. Gratzner HG. 1982. Science 218:474. 2. Dolbeare F, et al. 1983. Proc. Natl. Acad. Sci. USA 80:5573. 3. Dolbeare F, et al. 1985. Cytometry 6:521.
Gene ID: NA
Clone: Bu20a
Regulatory Status: RUO
Other Names: Bromodeoxyuridine
Isotype: Mouse IgG1, κ